[Evidence for Taxotere treatment with solid tumors]

Area of Science:

• Oncology
• Evidence-Based Medicine
• Pharmacology

Background:

• Evidence-based medicine is crucial for advancing cancer treatments.
• Taxotere (docetaxel) is a key chemotherapeutic agent for various solid tumors.
• International data exists for Taxotere, but domestic Japanese data requires specific review.

Purpose of the Study:

• To review and present the levels of evidence for Taxotere treatment in solid tumors.
• To analyze the efficacy and toxicity of Taxotere in Japanese patients based on domestic Phase II trial data.
• To compare Japanese findings with international clinical trial data from the USA and Europe.

Main Methods:

• Systematic review of existing literature on Taxotere for solid tumors.
• Analysis of Phase II clinical trial data from Japan for Taxotere approval.
• Comparative analysis of Japanese patient data with international (USA/Europe) clinical trial results.

Main Results:

• Domestic Japanese Phase II trials provide specific data on Taxotere's usefulness and toxicity in Japanese patients.
• International data predominantly supports Taxotere's application, with varying evidence levels.
• The review highlights the need to contextualize international findings within the Japanese patient population.

Conclusions:

• Japanese clinical trial data offers valuable insights into Taxotere's profile in local patients.
• A consensus among Japanese physicians and academies is necessary for optimal Taxotere application in solid tumors.
• Integrating domestic and international evidence is key for evidence-based cancer treatment strategies in Japan.